The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Antiangiogenic Cancer Therapy: Monitoring with Molecular US and a Clinically Translatable Contrast Agent (BR55)
Open accessAbstract
PURPOSE: To develop and test human kinase insert domain receptor (KDR)-targeted microbubbles (MBs) (MB(KDR)) for imaging KDR at the molecular level and for monitoring antiangiogenic therapy in a human colon cancer xenograft tumor model in mice. MATERIALS AND METHODS: Animal studies were approved by the Institutional Administrative Panel on Laboratory Animal Care. A heterodimeric peptide that binds to human KDR with low nanomolar affinity (K(D) = 0.5 nmol/L) was coupled onto the surface of perfluorobutane-containing lipid-shelled MBs (MB(KDR)). Binding specificity of MB(KDR) to human KDR and cross-reactivity with murine vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) were tested in cell culture under flow shear stress conditions (at 100 sec(-1)). In vivo binding specificity of MB(KDR) to VEGFR2 was tested in human LS174T colon cancer xenografts in mice with a 40-MHz ultrasonographic (US) transducer. Targeted contrast material-enhanced US imaging signal by using MB(KDR) was longitudinally measured during 6 days in tumors with (n = 6) and without (n = 6) antiangiogenic treatment (anti-VEGF antibody). Ex vivo VEGFR2 staining and microvessel density analysis were performed. Significant differences were evaluated (t, Mann-Whitney, or Wilcoxon test). RESULTS: Cell culture experiments showed four times greater binding specificity of MB(KDR) to human KDR and cross-reactivity to murine VEGFR2 (P < or = .01). In vivo imaging signal was more than three times higher (P = .01) with MB(KDR) compared with control MBs and decreased significantly (approximately fourfold lower, P = .03) following in vivo receptor blocking with anti-VEGFR2 antibody. One day after initiation of antiangiogenic therapy, imaging signal was significantly decreased (approximately 46% lower, P = .02) in treated versus untreated tumors; it remained significantly lower (range, 46%-84% decreased; P = .038) during the following 5 days. Microvessel density was significantly reduced (P = .04) in treated (mean, 7.3 microvessels per square millimeter +/- 4.7 [standard deviation]) versus untreated tumors (mean, 22.0 microvessels per square millimeter +/- 9.4); VEGFR2 expression was significantly decreased (>50% lower, P = .03) in treated tumors. CONCLUSION: Human MB(KDR) allow in vivo imaging and longitudinal monitoring of VEGFR2 expression in human colon cancer xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Cited by
Molecular imaging: current status and emerging strategies
Pysz, M. A., Gambhir, S. S., & Willmann, J. K. (2010) · Clinical Radiology · doi:10.1016/j.crad.2010.03.011 · Cited by 572
Self-citationApplications of nanoparticles for diagnosis and therapy of cancer
Baetke, S. C., Lammers, T., & Kiessling, F. (2015) · The British Journal of Radiology · doi:10.1259/bjr.20150207 · Cited by 494
Molecular imaging for cancer diagnosis and surgery
Hussain, T., & Nguyen, Q. T. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.007 · Cited by 337
Molecular ultrasound imaging: current status and future directions
Deshpande, N., Needles, A., & Willmann, J. K. (2010) · Clinical Radiology · doi:10.1016/j.crad.2010.02.013 · Cited by 306
Self-citationUltrasound Microbubbles for Molecular Diagnosis, Therapy, and Theranostics
Kiessling, F., Fokong, S., Koczera, P., Lederle, W., & Lammers, T. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.099754 · Cited by 305
Metadata
- Authors
- Pysz, M. A., Foygel, K., Rosenberg, J., Gambhir, S. S., Schneider, M., & Willmann, J. K.
- Venue
- Radiology
- Published
- 2010-08
- Volume
- 256
- Issue
- 2
- Pages
- 519-527
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2169346247
- Cited by
- 160
- References
- 3
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiangiogenic Cancer Therapy: Monitoring with Molecular US and a Clinically Translatable Contrast Agent (BR55). https://app.cochat.ai/papers/10.1148/radiol.10091858
- The paper
- Pysz, M. A., Foygel, K., Rosenberg, J., Gambhir, S. S., Schneider, M., & Willmann, J. K. (2010). Antiangiogenic Cancer Therapy: Monitoring with Molecular US and a Clinically Translatable Contrast Agent (BR55). Radiology. https://doi.org/10.1148/radiol.10091858
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.